Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

While chemo- and radio-therapy are considered the first-line of treatment for most cancers, its serious side effects have led to continuous innovation and discovery of new anti-tumor treatments. Oncolytic viruses (OVs) possess a magnitude of mechanism of action to elicit anti-tumor immune response, including OVs innate cytotoxicity and enhanced anti-tumor immunity by inserting immunomodulatory genes. …Read More >

AACR Annual meeting 2021 Wenrong Zhou1,* , Min Long2,3* , Tianyu Song3,* , Qiangqiang Fan1 , Zhengang Peng1 , Yong Cang3 , Qunsheng Ji1  1 Oncology and Immunology Unit, Research Service Division, WuXi AppTec (Shanghai) Co., Ltd., China; 2 Life Sciences Institute, Zhejiang University, Hangzhou, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, …Read More >

 AACR Annual meeting 2021   Authors: Zhixiang Zhang1, Feifei Fan2, Xiaohe Shi2, Xiangyang Zuo2, Qingyang Gu2, Qunsheng Ji1. 1 WuXi AppTec, Shanghai, China; 2 WuXi AppTec, Jiangsu, China Corresponding Author: Qunsheng Ji. Email: ji_qunsheng@wuxiapptec.com   Background  Many cancer types are driven by specific gene aberrances, like gene fusions, mutations and copy number changes. It has led to …Read More >

AACR Annual meeting 2021  Ting Ni, Zhixiang Zhang, Xuzhen Tang, Hui Qi, Jingying Zhang, Ke Mao, Wenting Shi, Qingyang Gu, Qunsheng Ji WuXi AppTec, Suzhou, China  Abstract Recent advances in cancer biology and diagnosis are providing more targeted approaches to treat cancers. Therapy targeting the specific oncogenic driver could inhibit tumor progression and helps to …Read More >

INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is on a mission to identify the next generation of cancer medicines that improve the lives of patients with cancer. He leads a multi-disciplinary team of scientists at The University of Texas MD Anderson Cancer Center’s Institute …Read More >

Biomarker discovery Mouse clinical trial 61 PDX-derived primary cancer cell lines Drug-resistant xenograft models Combination therapy platform including radiation World leading genome sequencing and bioinformatics capability